Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-2115
Abstract: Abstract Purpose: Alpelisib is a PI3K alpha (PI3Kα)-selective inhibitor approved for the treatment of hormone receptor–positive/HER2-negative (HR+/HER2−) PIK3CA-mutated advanced breast cancer (ABC) based on the SOLAR-1 trial, which defined 11 substitutions in exons 7, 9,… read more here.
Keywords: biology targetability; breast; alp ful; pik3ca mutations ... See more keywords